The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease—A cross sectional study  by Jørgensen, N.R. et al.
ARTICLE IN PRESSRespiratory Medicine (2007) 101, 177–1850954-6111/$ - s
doi:10.1016/j.r
E-mail addrThe prevalence of osteoporosis in patients with
chronic obstructive pulmonary disease—A cross
sectional study
N.R. Jørgensena, P. Schwarza, I. Holmeb, B.M. Henriksenc,
L.J. Petersend, V. BackerbaDepartment of Clinical Biochemistry, Copenhagen University Hospital Hvidovre, DK-2650 Hvidovre,
Denmark
bUnit of Respiratory Medicine, Department of Internal Medicine I, Copenhagen University Hospital
Bispebjerg, DK-2400 Copenhagen NV, Denmark
cDepartment of Radiology, Copenhagen University Hospital Bispebjerg, DK-2400 Copenhagen NV, Denmark
dDepartment of Clinical Physiology, Copenhagen University Hospital Bispebjerg, DK-2400 Copenhagen NV,
Denmark
Received 23 May 2005; accepted 25 March 2006KEYWORDS
Secondary
osteoporosis;
Corticosteroid
induced
osteoporosis;
COPD;
Vertebral fractures;
Pulmonary functionee front matter & 2006
med.2006.03.029
ess: niklas@dadlnet.dkSummary Chronic obstructive pulmonary disease (COPD) is a complex disease,
where the initial symptoms are often cough as a result of excessive mucus
production and dyspnea. With disease progression several other symptoms may
develop, and patients with moderate to severe COPD have often multiorganic
disease with severely impaired respiratory dysfunction, decreased physical activity,
right ventricular failure of the heart, and a decreased quality of life. In addition
osteoporosis might develop possibly due to a number of factors related to the
disease. We wanted to investigate the prevalence of osteoporosis in a population of
patients with severe COPD as well as to correlate the use of glucocorticoid treatment
to the occurrence of osteoporosis in this population. Outpatients from the
respiratory unit with COPD, a history of forced expiratory volume in 1 s (FEV1) less
than 1.3 L, with FEV1% pred. ranging from 17.3% to 45.3% (mean 31.4%, standard
deviation (SD) 7.3%). Patients between 50 and 70 years were included. Other causes
of osteoporosis were excluded before inclusion. At study entry spirometry, X-ray of
the spine (to evaluate presence of vertebral fractures), and bone mineral density of
lumbar spine and hip were performed. Of 181 patients invited by mail, 62 patients
were included (46 females and 16 males). All had symptoms of COPD such as
exertional dyspnea, productive cough, limitations in physical activity etc. The mean
FEV1 was 0.90 L (SD: 0.43 L) and the mean FEV1% pred. of 32.6% (SD: 14.1%). All had
sufficient daily intake of calcium and vitamin D. In 15 patients, X-ray revealedElsevier Ltd. All rights reserved.
(N.R. Jørgensen).
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osteoporosis in 22 patients and osteopenia in 16. In total, 26 of the COPD patients
were osteoporotic as evaluated from both X-ray and bone density determinations.
Thus 68% of the participants had osteoporosis or osteopenia, but glucocorticoid use
alone could not explain the increased prevalence of osteoporosis. A large fraction of
these needed treatment for severe osteoporosis in order to prevent further bone loss
and to reduce future risk of osteoporotic fractures. Thus, there is a significant need
to screen patients with COPD to select the individuals in risk of fracture and to
initiate prophylaxis or treatment for the disease.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
complex disease, where the initial symptoms are
often cough as a result of excessive mucus produc-
tion and dyspnea. With disease progression several
other symptoms may develop, and patients with
moderate to severe COPD often have multiorganic
disease with severely impaired respiratory dysfunc-
tion, decreased physical activity, right ventricular
failure of the heart, and a decreased quality of life.
As the disease progresses, osteoporosis becomes a
more prevalent finding in the COPD patient
population.1,2 Osteoporosis is characterized by
low bone mass with microarchitectural changes in
bone, which leads to an increased susceptibility to
fractures. The osteoporosis related fractures are
primarily located to the hip, wrist, and the thoracic
and lumbar spine. Fractures cause significant
morbidity to the patient, such as severe pain,
disabilities, decreased mobility, impaired respira-
tory function, and in worst case, death. Patients
with COPD have a multi organic illness initially
presenting as cough due to excessive mucus
production. These patients often have had immod-
est tobacco consumption for several years, but also
environmental and occupational factors may con-
tribute to the disease most likely as additive to the
effects of cigarette smoking. Episodes of muco-
purulent relapses increase in incidence and often
progresses into chronic obstructive disease. Per-
ipheral oedema as a result of right ventricular
failure may develop as well as cyanosis and the
patient may experience significant decreases in
quality of life due to respiratory dysfunction and
inactivity as well as anxiety. Osteoporosis is often
disabling in these patients, and may be equally
disabling as COPD it self. However, osteoporosis is
often undiagnosed in these patients, and may
impair respiratory function even further, if the
patient experiences vertebral compressions and
loss of height.1,3 Increased awareness is therefore
essential in order to diagnose and treat bone loss to
reduce the risk of fractures.Although COPD is a frequent illness with many
factors of possible importance for development of
several other diseases, only few but excellent
reviews on the relationship between COPD and
osteoporosis have been published.3–7 One of the
most obvious causes of osteoporosis in these patients
is treatment with glucocorticoids, both as systemic
therapy and as inhaled glucocorticoids.8–10 However,
the use of glucocorticoids in the treatment of COPD
is controversial, but most studies find only a
beneficial effect when administered to the most
severely affected patients with tendency to exacer-
bations.11–13 Glucocorticoid use does not fully
account for the low bone mineral density (BMD)
and high prevalence of osteoporosis in COPD
patients.3 Even in glucocorticoid naı¨ve patients,
BMD is found to be lower than in age-matched
control subjects, and consequently, fracture risk
higher.14,15 A number of factors have been suggested
to account for these findings. COPD patients are
often smokers, as well as they have impaired
mobility due to decreased muscle mass and respira-
tory dysfunction. Further, the group of patients with
the most severe COPD also have lower weight than
the general population, and low BMI is further a risk
factor of increased mortality.16 In COPD patients,
hypogonadism is also more frequent as hypogonad-
ism is commonly occurring in chronic diseases.3,14 All
these factors are known to pre-dispose to osteo-
porosis, and can explain the increased prevalence.
The present study has aimed at estimating the
frequency of osteoporosis in a homogenous popula-
tion of COPD patients with severe illness. Further,
we have evaluated the correlation between the
type and dose of corticosteroid intake and the
severity of osteoporosis.Methods
Study population and study design
All patients with a known diagnosis of COPD prior to
the present study and whom were followed at the
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Hospital were evaluated (n ¼ 995). From this
group, patients with severe airflow limitation
(FEV1o1.3 L which corresponded to FEV1% pred.
ranging from 17.3% to 45.3% (mean: 31.4%, SD: 7.3%)
were invited by mail during spring 1999 to
participate in the present study (n ¼ 181). Patients
were considered eligible for the study if they met
the following inclusion criteria: Alive at the time of
inclusion, age between 50 and 70 years; chronic
obstructive ventilatory insufficiency (FEV1/
FVCo70%) with no normalisation due to either
spontaneous variability or treatment. Patients
were excluded on the basis of one or more of the
following criteria: Rheumatic diseases or other
diseases affecting bone or calcium homeostasis,
including secondary hyperparathyroidism; endo-
crine diseases; asthma or established osteoporosis
under treatment with bone-active agents.
Ninety one (50%) of the 181 invited patients did
not respond or responded that they were not
interested in participating in the study, had died
since last follow-up at the out patient clinic, or had
moved out of the community. Of the 90 subjects
interested in participating, only 62 subjects (68% of
the ones interested in participating) were included,
as 10 patients answered after the study had
finished, 9 patients had established osteoporosis
(8 women, 1 man) and were excluded on that basis,
9 were excluded due to other reasons. Thus, 34% of
the invited study population was included.
A total of 62 COPD patients with a mean (7SD)
age of 63.2 (75.4) years were eligible for inclusion
in the study, of whom 46 were female and 16 male.Table 1 Demographic data for all study participants and
Mean (7 SD), all
participants
Age (years) 63.2 (7 5.4)
Height (cm) 164.2 (7 8.5)
Spirometry
FEV1 (L) 0.90 (7 0.43)
FVC (L) 1.67 (7 0.59)
FEV1% predicted 32.6 (7 14.1)
FVC % predicted 43.8 (7 12.3)
Bone density
BMD lumbar spine (g/cm2) 1.027 (7 0.198)
BMD femoral neck (g/cm2) 0.833 (7 0.162)
T-score lumbar spine 1.54 (7 1.27)
T-score femoral neck 1.49 (7 1.63)
Smoking habits
Tobacco pack-years 37.3 (7 12.5)
SD: standard deviation; FEV1: forced expiratory volume in 1 s; FVAll patients were treated with a daily dose of
500mg calcium and 5 mg of vitamin D. Nine patients
were in continuous oral glucocorticoids treatment.
Two of these were treated with doses correspond-
ing to more than 7.5mg and the remaining 7 were
treated with 2.5–7.5mg/day. The pulmonary func-
tion was registered with a mean absolute FEV1 ¼
0.90 (70.43) L and mean absolute FVC ¼ 1.67
(70.59) L. Percent predicted of normal values for
FEV1 was 32.6% (714.1) (range 9.0–82.4%) and for
FVC 43.8 (712.3) (range 19.5–83.1%). Thus, ac-
cording to the GOLD guidelines patients were
classified as having moderate to severe in the III
and IV groups. None of the participants had
respiratory insufficiency and were using oxygen at
home. Baseline demographic data are shown in
Table 1. All patients had normal biochemical
evaluations, as patients with changes in calcium
metabolic parameters were excluded.
The study was designed as a cross-sectional
study, based on historical data on concomitant
medication combined with clinical data and a
questionnaire obtained at the study visit at the
outpatient clinic. The study was approved by the
Danish Ethics Committee, and study subjects had
signed informed consent before performing any
study-related procedures.
Methods
Basic demographic and clinical data were collected
during June through September 1999 using a
questionnaire concerning: Age, gender, previous
bone fractures, present and previous medication,for males and females separately.
Mean (7 SD), male
participants
Mean (7 SD), female
participants
62.8 (7 5.8) 63.4 (7 5.3)
174.1 (7 7.2) 160.8 (7 5.9)
1.07 (7 0.61) 0.84 (7 0.34)
2.21 (7 0.82) 1.49 (7 0.35)
35.1 (7 19.3) 31.8 (7 12.1)
49.2 (7 17.1) 42.0 (7 9.8)
1.089 (7 0.252) 1.005 (7 0.174)
0.888 (7 0.138) 0.814 (7 0.167)
1.25 (7 2.08) 1.58 (7 1.47)
1.51 (7 1.08) 1.54 (7 1.34)
44.9 (7 10.3) 34.6 (7 12.2)
C: forced vital capacity; BMD: bone mineral density.
ARTICLE IN PRESS
N.R. Jørgensen et al.180tobacco consumption (pack years), daily exercise,
daily diet and duration of the respiratory disease.
Bone status was determined by radiology assess-
ments and by measurement of bone mineral para-
meters. X-rays of the thoracic and lumbar spine in
two projections were performed. The X-rays were
evaluated based on the international criteria. The
evaluating radiologist was blinded to the patient’s
use of glucocorticoids, actual level of lung function or
other factors of possible importance. Bone mineral
parameters were performed using a Lunar DFXIQ 5001
densitometer. BMD, bone mineral content (BMC), and
area were measured at the lumbar spine (vertebrae
L2–L4) and at the femoral neck. All parameters were
expressed in standard globally accepted terms:
BMD (g/cm2), BMC (g), and area (cm2). Standardised
T-score analyses were used to compare individual
bone density determinations for study subjects to
those of a young normal control population of the
same gender. This was done to standardize the BMD
measurements to peak bone mass, which occurs at
30 years of age. The BMD measured is therefore
correlated to the peak bone mass and is expressed as
a T-score which is the number of standard deviations
below or above peak bone mass for the relevant
gender. T-score values between 1.0 and 2.5 are
definable for osteopenia and T-scores below 2.5 are
definable for osteoporosis17.
Basic laboratory parameters were analyzed in
order to exclude patients with other causes of
osteoporosis. The following parameters were de-
termined: B-haemoglobin, B-sedimentation ratio,
P-creatinin, P-sodium, P-albumin, P-Ca2+, P-cal-
cium (total), S-25-OH-vitamin D, U-creatinin,
U-calcium, P-alkaline phosphatase, S-parathyroid
hormone.
Pulmonary function test: Absolute values of
FEV1, FVC, and reversibility were performed on a
dry-spirometer of the ‘‘bell-spirometer’’ type with
the patient in the seated position. Bricanyl was
used as bronchodilator. Three measurements were
performed and the best results of the three post-
bronchodilator determinations were noted. The
discrepancy between the highest and lowest value
was less than 5%. Percent predicted of normal
values for FEV1 and FVC were calculated according
to formulas from Cherniak, pulmonary function
testing18 as they are suitable for use in caucasians
above 18 years of age. Different formulas were
used for men and women.Statistics
All statistical analyses were performed using the
SPSS statistical software package, version 11.5(SPSS Inc., Chicago, IL). All results are presented
as mean 72 standard deviations (7SD) in descrip-
tion of the demographic data. In the comparison
between different groups, results are presented as
mean7standard error of the mean (SEM). Analysis of
variance (ANOVA) has been used as statistical test
to compare means in cases where parametric
results are handled. Students T-test has been used
in cases where two groups of parametric data were
compared. Nominal data were compared using the
w2 test.
T score is a statistical transformation of data that
represents a measure of the number of standard
deviations from mean peak bone mass of normal
individuals of the same gender. Each decrease in
BMD of one standard deviation increases the risk of
an osteoporotic fracture by 100%. Osteopenia is
defined as a T-score between 1.0 and 2.5
standard deviations. Osteoporosis is defined as a
T-scorep2.5 standard deviation according to the
1994 WHO criteria, and/or one or more low-energy
fractures (hip or spine).Results
Prevalence of osteoporotic fractures
X-ray examination of the vertebral spine was
performed for all 62 study participants. X-rays
were analyzed for presence of compression
fractures. 15 patients (12 women and 3 men)
were found to have one or more previously
undiagnosed osteoporotic compression fracture
when analysed. This should be seen in contrast
to, that only 9 had previously diagnosed
fractures prior to the study inclusion. Mean age
(7SEM) was 64.5 (71.1) years, compared to
62.8 (70.8) years for the non-fracture group.
Lung function in FEV1 and FVC for both absolute
and % predicted of normal values were compared
between the fracture and the non-fracture
group and results are shown in Table 2. No
significant differences in lung function could be
demonstrated between the two groups (Table 2 and
Fig. 1a). We also tested for differences in smoking
habits, but no differences between the fracture
and non-fracture groups in tobacco pack-years
could be detected. However, as expected a
significant difference in BMD at the lumbar
spine was detected between the fracture and
non-fracture group, showing a higher bone mass
in the non-fracture group. Further, a higher
percentage of patients in glucocorticoid treatment
was found in the fracture group (36.4%) compared
to the non-fracture group (11.6%) (Table 2),
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Table 2 Comparison of age, lung function tests, bone density parameters, and number of patients with
continuous glucocorticoid treatment between the group of patients with newly diagnosed vertebral fractures and
the non-fracture group.
Fracture group n ¼ 15,
mean (7SEM)
Non-fracture group
n ¼ 37, mean (7SEM)
P-value
Age (years) (n ¼ 62) 64.5 (71.1) 62.8 (70.8) 0.29
Spirometry (n ¼ 56)
FEV1 (L) 0.87 (70.17) 0.91 (70.05) 0.82
FVC (L) 1.64 (70.21) 1.68 (70.08) 0.83
FEV1% predicted 31.6 (75.6) 32.9 (71.7) 0.77
FVC % predicted 43.1 (74.7) 44.0 (71.6) 0.81
Bone density (n ¼ 54)
BMD lumbar spine (g/cm2) 0.895 (70.043) 1.060 (70.030) 0.01
BMD femoral neck (g/cm2) 0.751 (70.048 0.854 (70.024) 0.06
T-score lumbar spine 2.64 (70.35) 1.20 (70.25) o0.01
T-score femoral neck 2.17 (70.41) 1.37 (70.18) 0.06
Smoking habits (n ¼ 61)
Tobacco pack-years 38.2 (72.4) 37.0 (72.0) 0.76
% glucocorticoid treated (n ¼ 54) 36.4% 11.6% 0.07
n: number of individuals; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; BMD: bone mineral density; SEM:
standard error of the mean.
COPD and osteoporosis 181suggesting a detrimental effect of glucocorticoids
on bone strength.Bone mineral density
Of the 62 patients included, 54 had DXA scans of
the hip and lumbar spine performed. Subjects were
grouped according to the WHO criteria, and
diagnosed as osteoporotic, osteopenic, or normal
bone mass according to T-score for BMD. The lowest
T-score at either region determined the diagnosis.
Thus, if the T-score at either region was below
2.5, the individual was diagnosed as having
osteoporosis. If the lowest T-score at either region
was between 2.5 and 1.0 the subject was
diagnosed with osteopenia. If both hip and lumbar
spine T-score was above 1.0 the study subject was
grouped as having normal bone mass. Of 54
evaluable patients, 22 patients were diagnosed as
having osteoporosis by BMD alone. Sixteen were
osteopenic and 16 had normal bone mass. The
three disease groups did not differ in age, nor did
they show statistically significant differences with
respect to absolute or % predicted of normal values
of FEV1, FVC or tobacco pack-years (Table 3 and
Fig. 1b).
Of the patients diagnosed with osteoporosis
according to BMD measurements, 4 had continuous
glucocorticoid treatment, while only one in the
osteopenic group and 3 in the group with normal
bone mass were continuously treated with gluco-corticoids. This distribution was not found signifi-
cant by statistical testing. Finally, the number and
percentage of vertebral fractures in three BMD
groups were determined. In the group with normal
BMD, only 1 patient had a fracture, while 3 in the
osteopenic group and 7 in the osteoporotic group
had one or more vertebral fractures. However, this
result was not found to be significant upon
statistical testing.Prevalence of osteoporosis in a group of
COPD patients
The diagnosis of osteoporosis is based both of bone
mass measurements and the knowledge of previous
low-energy fractures in the individual patient. In
this study, we obtained information of both
vertebral fractures and bone mass. Combining
these data, we found that out of 58 evaluable
patients, 26 patients (44.8%) were osteoporotic,
while 13 (22.4%) were osteopenic and 15 (25.9%)
had normal bone mass. Of the patients diagnosed
with osteoporosis 5 had continuous glucocorticoid
treatment, while one in the osteopenic group and 3
in the group with normal bone mass. No statistically
significant differences could be detected between
the three groups with respect to glucocorticoid use
(Table 4). We also tested for differences in smoking
habits, but no differences between the osteoporo-
tic and non-osteoporotic groups in tobacco pack-
years could be detected.
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Figure 1 Shows the relationship between lung function
and the presence of one or more vertebral fractures in
the COPD patients in the study. Average forced expiratory
volume in 1 s (FEV1) is shown for four different groups:
patients without vertebral fractures not receiving con-
tinuous glucocorticoid treatment (‘‘no fracture—GC’’),
patients without vertebral fractures treated with con-
tinuous glucocorticoids (‘‘no fracture+GC’’), patients
with one or more vertebral fractures not receiving
glucocorticoids (‘‘fracture—GC), and finally patients
with fracture treated with continuous glucocorticoids
(‘‘fracture+GC). Error bars show standard error of the
mean. BMD: bone mineral density; FEV1: forced expira-
tory volume in 1 s; GC: glucocorticoid.
N.R. Jørgensen et al.182Discussion
The present study shows a high prevalence of
osteoporosis among patients with severe COPD(GOLD IIb and III). The group of patients studied is
likely to represent the large number of COPD
patients followed in the pulmonary out-patient
clinics throughout the world. Most countries have
guidelines concerning long-term corticosteroid
treatment and prevention of secondary osteoporo-
sis, but no countries have guidelines concerning
osteoporosis in COPD patients with or without
glucocorticoid treatment (oral and inhaled). In
the recent years, COPD rehabilitation programs
have been part of daily routine, including dietician,
activity and smoking cessation and furthermore,
use of steroids are recommended due to GOLD
classification to be restricted to patients with
numerous exacerbations per year. In line with other
studies, we show that although glucocorticoid
treatment is a major risk factor for osteoporosis
in chronically treated COPD patients, other risk
factors independent of corticosteroids, but related
to the disease, exist. This is evident, as we did not
find any difference in prevalence of glucocorticoid
treatment in the osteoporotic group versus the
group having normal bone mass. A reason for these
findings might be that data concerning intake of
steroids are retrospectively collected. These risk
factors may assume greater significance when the
total dose of steroids is low, as in the case of
inhalation steroids.19 Further, in this study, we do
not have information regarding the length of
corticosteroid treatment, as no valid information
regarding length of treatment was available, and
thus the number of years patients have been
exposed to this medication could not be deter-
mined. Thus, in order to determine the exact
contribution of glucocorticoids to osteoporosis and
fractures in COPD patients prospective studies with
collection of data for glucocorticoid dose and
length of treatment are necessary. Furthermore,
the sample size in this study may also influence the
results. The power and the number of patients in
glucocorticoid treatment surely invalidates the
statistical determination of the influence of risk
factors on osteoporosis development.
However, COPD patients have several other risk
factors that might contribute to development of
osteoporosis such as smoking and inactivity, and
these factors might be as important as glucocorti-
coids as risk factors in these patients. Smoking
habits are clearly a risk factor for both osteoporosis
and COPD, and could potentially interfere with our
results. In the current study we collected informa-
tion on the patients’ number of pack-years, but we
could not detect any differences in smoking habits
between osteoporotic patients and non-osteoporo-
tic patients. This does not indicate that smoking is
not a risk factor of osteoporosis, but it might
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Table 3 Comparison of age, lung function tests, glucocorticoid (GC) treatment, and incidence of vertebral
fractures between osteoporotic and osteopenic COPD patients, and COPD patients with normal bone mass.
Normal BMD
(n ¼ 16), mean
(7SEM)
Osteopenic BMD
(n ¼ 16), mean
(7SEM)
Osteoporotic BMD
(n ¼ 22), mean
(7SEM))
P-value
Age (years) (n ¼ 54) 62.4 (71.5) 64.2 (71.1) 63.3 (71.3) 0.83
Spirometry (n ¼ 50)
FEV1 0.91 (70.10) 1.03 (70.15) 0.76 (70.07) 0.26
FVC 1.62 (70.14) 1.82 (70.20) 1.58 (70.12) 0.65
FEV1% predicted 33.2 (73.0) 36.7 (74.4) 28.0 (72.4) 0.24
FVC % predicted 43.3 (72.4) 46.3 (73.7) 41.7 (72.7) 0.68
Smoking habits (n ¼ 61)
Tobacco pack-years 35.3 (74.0) 38.0 (73.4) 37.6 (72.0) 0.89
No. of continuously GC
treated (n ¼ 54)
3 (18.8%) 2 (12.5%) 4 (18.2%) 0.87
No. with vertebral fracture
(n ¼ 54)
1 (6.3%) 3 (18.8%) 7 (31.8%) 0.15
n: number of individuals; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; BMD: bone mineral density; SEM:
standard error of the mean.
Table 4 Comparison of lung function tests and number of continuously glucocorticoid (GC) treated COPD
patients in the osteoporotic group, as determined by a bone mineral density (BMD) T-score at either site of
measurement o2.5 and/or presence of a vertebral fracture on X-ray of the vertebral spine versus the non-
osteoporotic group, as determined by a BMD T-score at both spine and hip of42.5 and no vertebral fractures on
X-ray.
Osteoporotic group
n ¼ 26, mean (7SEM)
Non-osteoporotic group
n ¼ 28, mean (7SEM)
P-value
Age (years) (n ¼ 62) 63.6 (71.0) 62.9 (71.0) 0.63
Spirometry (n ¼ 56)
FEV1 (L) 0.86 (70.09) 0.93 (70.07) 0.56
FVC (L) 1.69 (70.13) 1.65 (70.10) 0.83
FEV1% predicted 31.4 (73.2) 33.8 (72.1) 0.54
FVC % predicted 44.2 (72.9) 43.4 (71.7) 0.80
Smoking habits (n ¼ 61)
Tobacco pack-years 37.3 (71.6) 37.3 (72.7) 0.98
No. of continuously GC treated
(n ¼ 54)
19.2% 14.3% 0.63
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SEM: standard error of the mean.
COPD and osteoporosis 183suggest that some people do not respond to
smoking with decreased bone mass. However, in
addition to a genetic component, osteoporosis is
strongly affected by environmental factors, and
these patients are probably exposed to a number of
other factors that might outweigh the effects of
smoking on the bones.
Previous papers indicate the need of primary
osteoporosis prophylaxis and the estimation of BMD
when glucocorticoid treatment is initiated,20,21 but
only few articles focus on secondary osteoporosis
relating to inhaled steroid treatment.22,23 In con-
trast to these studies, other long-term surveys havefailed to demonstrate any detrimental effect of
inhaled steroids on bone mass.24,25
Our results show reduced BMD (osteopenia or
osteoporosis) in approximately 75% of the study
group, where a large number of these would be
eligible for anti-osteoporotic therapy according to
the treatment guidelines in Denmark, as the
present group of COPD patients were classified as
moderate to severe COPD (GOLD III and IV). None of
the patients suffered from any symptoms related to
fracture of the vertebrae. Thus, a large number of
patients have established osteoporosis, though they
do not receive any treatment. They might have
ARTICLE IN PRESS
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osteoporosis is not given to these patients, thus
withholding proper and necessary treatment to
prevent further fractures and disability of the
patient.
Another reason for the high prevalence of
osteoporosis in COPD patients is most likely that
there among these patients is a predominance of
women. In our study, we see a predominance of
women. The incidence of osteoporosis is higher in
women than in men, and it could be expected that
women with COPD therefore would be even more
susceptible to develop osteoporosis than women
with normal lung function. It is well-established
that women are more prone to develop COPD even
if they on an average basis do not smoke as much as
men. This is partially because they are less
resistant to the harmful side effects of smoking
than men, but also that women live longer, and live
to an older age with their lung disease.26
At study start almost 50% of the initial contacted
group did not respond. A number of these were
expected to have died, and may thus have had the
most severe COPD. Another reason for the patients
not to respond could be that they were immobilized
and could thus not answer the invitation. Some of
the patients were also suspected to have respira-
tory insufficiency being treated with oxygen at
home, and were therefore not able to leave the
home. As they non-responders thus are suspected
to have the most severe COPD, we would therefore
expect these to have an even higher prevalence of
osteoporosis. The patients included in this study
would therefore be the least ill patients, so the
prevalence of bone disease in this study could very
well be underestimated, meaning that the problem
in the most severely affected COPD population is
even bigger than documented. However, we do not
have any direct data documenting the respiratory
status of the non-responders other than they have
moderate to severely decreased lung function. This
may bias the results of the study and it could be
questioned whether the low participation rate
makes it possible to generalize the results of this
study to all COPD patients followed in out-patient
clinics worldwide. Naturally, the data are only
representative of the included population, but as
mentioned above there is no reason to think, that
the non-responders will have less significant osteo-
porosis than the included patients.
As expected, no statistically significant differ-
ences in the pulmonary function were detected
between osteoporotic, osteopenic, and normal
individuals. FEV1 was lower compared to the
inclusion criteria (FEV1p1.3 L), which is as ex-
pected. The group with osteoporotic fractures wererecruited to the study as non-osteoporotic COPD
patients, as they had no known history of osteo-
porosis, but as the results show, they are troubled
with very low pulmonary function and osteoporosis.
The previously unknown fractures may cause back
pain and as a result of pain, limitation of the
thoracic movements. This may cause pneumonia
and further decreased pulmonary function and
even lead to further steroid treatment and inactiv-
ity. Thus, osteoporotic vertebral fractures in COPD
patients lead to a vicious cycle, where if the
problem is not recognized and treated, the
patients’ pulmonary function will decline rapidly.
Surprisingly, we were unable to detect a sig-
nificant difference in the number of fractures when
comparing the three BMD groups (normal, osteo-
penic, and osteoporotic). This is presumably due to
low power of the study with respect to this
parameter, as we only see one individual with a
vertebral fracture in the normal group. However,
when we look at the percentage of individuals with
fractures in the three BMD groups, a clear tendency
towards increased fracture risk is apparent as the
percentage of individuals with fracture increases
from 6.3% in the group with normal BMD, 18.8% in
the osteopenic group to 31.8% in the osteoporotic
group. Thus, a larger number of individuals should
be included in order to detect significant differ-
ences in fracture risk. Another limitation of the
study is that no age- and gender-matched control
group has been included. For the determination of
BMC we have correlated the measurements of BMD
to the values at peak bone mass for a young normal
control population in order to standardize the
measurements. Values were expressed as T-scores.
This was further done as T-scores are actually
definable for osteoporosis and osteopenia. How-
ever, this does not give information on which
osteoporosis prevalence to expect in the patient
population. In this study we have only used
historical controls, but the use of an age- and
gender matched control group in combination with
a larger sample size/power would have strength-
ened the study. However, it could be discussed
which population should be used as a control group.
It is evident that they should be healthy and be age-
and gender matched to the patients included in the
study, but as there are many risk factors for
osteoporosis in COPD patients, the outcome and
the validity of the conclusions would definitely
depend on whether the controls are smokers/non-
smokers, have low/normal body weight, etc.
Despite the limitations of this study there is no
doubt that osteoporosis is a major problem in COPD
patients, and patients with severe COPD should
have performed diagnostic X-ray/DXA in order to
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tures or DXA verified osteoporosis, anti-osteoporo-
tic treatment should be initiated 7. This serves two
purposes: to reduce future risk of new vertebral
fractures, and to slow the onset of terminal COPD,
which can be the cause of evolving osteoporosis.
Osteopenic patients should be followed closely in
order to start anti-osteoporotic treatment as soon
as necessary before vertebral fractures occur.
Further, if the patient is continuously treated with
glucocorticoids, treatment should be initiated
already in osteopenic patients according to local
recommendations.
In conclusion, the present study showed that
there is a high prevalence of accelerated bone loss
in the COPD patient population, and that it is
important to screen these patients for osteoporosis
in order to initiate treatment for the disorder
before they develop fractures. Further studies are
needed to determine whether this is also true for
COPD patients with less severe respiratory disease,
and subsequently determining the need for pre-
vention of bone loss in this population.References
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